Controlled Substance Class
Varenicline is not a controlled substance.

Humans:

* Fewer than 1 out of 1000 patients reported euphoria in clinical trials with Varenicline.
At higher doses (greater than 2 mg), Varenicline produced more frequent reports of gastrointestinal disturbances such as nausea and vomiting.
There is no evidence of dose-escalation to maintain therapeutic effects in clinical studies, which suggests that tolerance does not develop.
Abrupt discontinuation of Varenicline was associated with an increase in irritability and sleep disturbances in up to 3% of patients.
This suggests that, in some patients, varenicline may produce mild physical dependence which is not associated with addiction.

* In a human laboratory abuse liability study, a single oral dose of 1 mg varenicline did not produce any significant positive or negative subjective responses in smokers.
In non-smokers, 1 mg varenicline produced an increase in some positive subjective effects, but this was accompanied by an increase in negative adverse effects, especially nausea.
A single oral dose of 3 mg varenicline uniformly produced unpleasant subjective responses in both smokers and non-smokers.

Animals:

Studies in rodents have shown that varenicline produces behavioral responses similar to those produced by nicotine.
In rats trained to discriminate nicotine from saline, varenicline produced full generalization to the nicotine cue.
In self-administration studies, the degree to which varenicline substitutes for nicotine is dependent upon the requirement of the task.
Rats trained to self-administer nicotine under easy conditions continued to self-administer varenicline to a degree comparable to that of nicotine, however in a more demanding task, rats self-administered varenicline to a lesser extent than nicotine.
Varenicline pretreatment also reduced nicotine self-administration.